🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
VER
$VERU
🔒 US EquitiesVeru Inc
AVG HISTORICAL GAP
-1.72%
MAX GAP RECORD
-13.26%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $VERU
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$VERU
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 10, 2026 Earnings Release 2026-08-10 (BEFORE OPEN) |
+5.15%
|
| May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN) |
+0.88%
|
| Feb 11, 2026 Earnings Release 2026-02-11 (BEFORE OPEN) |
+0.43%
|
| Dec 17, 2025 Earnings Release 2025-12-17 (BEFORE OPEN) |
+0.41%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (BEFORE OPEN) |
-9.75%
|
| May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN) |
+0.00%
|
| Feb 13, 2025 Earnings Release 2025-02-13 (BEFORE OPEN) |
-3.64%
|
| Dec 16, 2024 Earnings Release 2024-12-16 (AFTER CLOSE) |
-3.80%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
3.5%
Bullish Gaps (3)
Bearish Gaps (4)
Neutral / Flat (5)
📖 Intelligence Summary
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗